Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Ранг среди акций #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Цена акции
$0.38
Последняя синхронизация: 2023-09-01
Рыночная капитализация
$677.16K
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Aceragen, Inc. (ACGN)

Категория

Коэффициент P/S для Aceragen, Inc. (ACGN)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Aceragen, Inc., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Aceragen, Inc. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE